# Page 1
To obtain administrative approval for procurement of Rapid Kits and Drugs for Hepatitis B and Hepatitis C under NVHCP Programme.
The Government of Maharashtra
the Department of Public Health
Government Resolution No: PRASHAMA-1221/ PR No. 04/ HEALTH-7
10th Floor, Hospital Building
New Ministry, Mumbai- 400001.
Date: July 6, 2022
(1) Government Resolution, Department of Public Health, No: PRASHAMA-1221/ PR No. 04/ HEALTH-7, dated: 02.02.2021.
(2) Letter from Joint Director (Hospitals), Commissionerate of Health Services, Mumbai No: RASO/ NVHCP/ Kits& Medicines/ Administrative Approval/ 122790/ 2022, dated: 03.03.2022.
(3) Government Decision, Department of Public Health, No. 1221/ Q. No. 04/ Health-7, dated:
31.03.2022.
(4) Letter from Joint Director (Hospitals), Commissionerate of Health Services, Mumbai No: RASO/ NVHCP/ Kits& Medicines/ Administrative Approval/ 79807-811/2022, dated: 26.06.2022.
(5) Government Resolution, Public Health Department, No: Purchase-2016/ PR No.240/ Health-8, dated: 26.07.2017.
Preamble: In pursuance of the decision of the Government under Reference No. (1), the tender process for procurement of Rapid Kits for screening of Hepatitis B and Hepatitis C at 9 Model Treatment Centres (MTCs) and 27 Treatment Centres (TCs) under National Viral Hepatitis Control Programme (NVHC) in 35 districts of the State was accorded administrative approval with a budget of Rs. 85.30 lakh under the project implementation plan PIP FMR Code 6.2.23.2 and PIP FMR Code 6.2.23.1 for the year 2020-21. Meanwhile, the Joint Director (Hospitals), Commissionerate of Health Services, Mumbai, vide Reference Letter No. (2), had requested for administrative approval for the procurement of Hepatitis B and C Rapid Kits and Medicines and Injections under NVHCP Programme for the financial year 2021-22 at an estimated cost of Rs. Accordingly, administrative approval was accorded for the estimated cost of procurement of Rs. 7,18,54, 500/-for the subject purpose under Reference No.
# Page 2
Government Resolution No: PRASHAMA-1221/ PR No. 04/ HEALTH-7
However, now a letter under reference by Joint Director (Hospitals), Commissionerate of Health Services, Mumbai
No. (4) informs the Government that Haffkine Biopharmaceuticals Corporation has developed Hepatitis B
The prices of rapid kits and medicines and injections of C have not been determined yet. In fact,
Haffkine Biopharmaceuticals should be regulated by the Corporation and the rates should be determined by the Rapid
To give administrative approval for the purchase of Kits and medicines for the next two years instead of 2021-22.
He urged the government to reconsider its decision. the Commissionerate of Health Services
Haffkine Jeeva by superseding the decision of the Government of Reference No. (3) in accordance with the request made
As per the decision taken by the Pharmaceuticals Corporation of India, the price of the drug will be fixed by 2022.
Hepatitis B and C under NVHCP programme for the next two financial years 2023-24
Administrative approval of estimated cost of purchase of Rapid Kits and Medicines and Injections
It was under the consideration of the government.
Government's decision:
National Viral Hepatitis as proposed by the Commissionerate of Health Services
(NVHCP) for the year 2022-23 and 2023-24 instead of 2021-22.
Haffkine Biopharma to procure Hepatitis B and C Rapid Kits for two years
Corporation, Mumbai after determining the rates, proposed to be determined by the Corporation
Details of the purchase are as follows:
" Details of the proposed purchase"
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| Table I.. Rapid Kits Budget Requirement (Apporox.) |
| Sr. No.                                            | Name of Rapid Kit                           |             | Rate per Kit ( In Rs.) | Quantity (No. of test/Kit) | Budget Required (In Rs.) | Total Budget Required for 2 Years (In Rs.) |
| 1st Year                                           | 2nd Year                                    | 1st Year    | 2nd Year               |
| 1                                                  | Hepatitis B Rapid Kit (Serum/Plasma bases ) | 12          | 8,19,000               | 8,19,000                   | 98,28,000                | 98,28,000                                  |           |           | 1,96,56,000 |
| 2                                                  | Hepatitis B Rapid Kt (Whole blood)          | 20          | 91,000                 | 91,000                     | 18,20,000                | 18,20,000                                  | 36,40,000 |
| 3                                                  | Hepatitis B ELISA Kit (96 tests)            | 1,000       | 1,000 Kit              |                            | 1,000 Kit                |                                            | 10,00,000 | 10,00,000 |             | 20,00,000 |
| 4                                                  | Hepatitis C Rapid Kit (Serum/Plasma bases)  | 15          | 2,46,150               | 2,46,150                   | 36,24,750                | 36,24,750                                  |           |           | 72,49,500   |
| 5                                                  | Hepatitis C Rapid Kit (Whole blood)         | 20          | 26,850                 | 26,850                     | 5,37,000                 | 5,37,000                                   | 10,74,000 |
| 6                                                  | Hapatitis C ELISA Kit (96 tests)            | 1,000       | 350 Kit                | 350 Kit                    | 3,50,000                 | 3,50,000                                   | 7,00,000  |
| Total...                                           | 17159750                                    | 1,71,59,750 | 3,43,19,500            |
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Page 2 of 6
# Page 3
Government Resolution No: PRASHAMA-1221/ PR No. 04/ HEALTH-7
Haffkine Biopharmaceuticals to procure Rapid Kits for Hepatitis B and C
After determination of rates by the Corporation, Mumbai, PIP as per the determination of the Corporation
Rs.3,43,19,500/- (Rupees Three) out of the subsidy available under the head' FMR Code 6.2.23.2'.
the proposed estimated administrative expenses of Rs. Thirty-three lakhs and Nineteen thousand and Five hundred only)
It's approved.
Also, under the NVHCP programme, as proposed by the Ministry of Health Services
Hepatitis B q C for two years 2022-23 and 2023-24 instead of 2021-22
Haffkine Biopharmaceuticals Manufacturing Corporation, Mumbai for procurement of Drugs and Injections
After that, the details of the proposed purchase, estimated according to the determination of the corporation, are as follows:
" Details of the proposed purchase"
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| Table II.. NVHCP Medicine Budget Requirement (Apporox.) |
| Sr. No.                                                 | Name of Medicine                                       | Rate per Tab/ Inj ( In Rs.) | Quantity    | Budget Required (In Rs.) | Total Budget Required for 2 Years ( In Rs. ) |
| 1st Year                                                | 2nd Year                                               | 1st Year                    | 2nd Year    |
| Hepatitis B Medicine                                    |
| 1                                                       | Tab Entecavir (Ent 0.5 mg)                             | 11                          | 40,000      | 40,000                   | 4,40,000                                     | 4,40,000    | 8,80,000    |
| 2                                                       |                                                        | Tab Entercavie (Ent 1mg )   | 13          | 10,000                   | 10,000                                       | 1,30,000    | 1,30,000    | 2,60,000    |
| 3                                                       | Tab Tenofovir 300 mg                                   | 7                           | 40,000      | 40,000                   | 2,80,000                                     | 2,80,000    | 5,60,000    |
| Hepatitis C Medicine                                    |
| 4                                                       | Tab Daclatasvir 30 mg                                  | 9                           | 9,000       | 9,000                    | 81,000                                       | 81,000      | 1,62,000    |
| 5                                                       | Tab Daclatasvir 60mg                                   | 9                           | 13,500      | 13,500                   | 1,21,500                                     | 1,21,500    | 2,43,000    |
| 6                                                       | Tab Sofosbuvir 400 mg                                  | 22                          | 9,000       | 9,000                    | 1,98,000                                     | 1,98,000    | 3,96,000    |
| 7                                                       | Tab Sofosbuvir 400 mg + Velpatasvir 100 mg             | 75                          | 54,000      | 54,000                   | 40,50,000                                    | 40,50,000   |             | 81,00,000   |
| 8                                                       | Tab Ribavirin 200 mg for Hepatitis C complicated cases | 6                           | 4,500       | 4,500                    | 27,000                                       | 27,000      | 54,000      |
| Prophylaxis                                             |
| 9                                                       |                                                        | Inj HBIG                    | 1,920       | 7,000                    | 7,000                                        | 1,34,40,000 | 1,34,40,000 | 2,68,80,000 |
| Total...                                                | 1,87,67,500                                            | 1,87,67,500                 | 3,75,35,000 |
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Haffkine Biopharma for purchase of Hepatitis B and C drugs and injections
After determination by the Construction Corporation, Mumbai, as per the determination of the Corporation," PIP FMR
Code 6.2.23.1" Out of the grant available under this head, Rs. 3,75,35, 000/- (Rupees Three Crores)
seventy-five lakh thirty-five thousand only) to give administrative approval to the proposed estimated cost of
It's coming
Page 3 of 6
# Page 4
Government Resolution No: PRASHAMA-1221/ PR No. 04/ HEALTH-7
In this regard, the proposed expenditure estimated at Rs. 7,18,54, 500/- (Rupees Seven Crores Eighteen Lakhs Fifty Five Thousand Only) for procurement of Rapid Kits and Drugs and Injections for Hepatitis B and C under NVHCP Programme for two financial years 2022-23 and 2023-24 respectively is being administratively approved at a total cost of Rs.3,43,19,500/- (Rupees Three Crores Thirty-three Lakhs Nineteen Thousand Five Hundred Only) and Rs. 3,75,35, 000/- (Rupees Three Crores Seventy-five Lakhs Thirty-five Thousand Only) subject to the following conditions:
(1) After the determination of the rates by Haffkine Biopharmaceuticals Manufacturing Corporation, Mumbai, the Commissionerate of Health Services shall first ascertain the requirement/ demand for the purchase of Rapid Kits, Medicines and Injections for Hepatitis B and C as per the determination of the Corporation.
Thereafter, the tender process will be initiated.
(2) It should be ensured that the specifications of such rapid kits, medicines and injection materials are as per the requirement and up-to-date. The technical specifications of the items to be procured should be as per the specifications agreed by the concerned experts (Technical Committee/ Officials).
(3) It shall be ensured that the technical specifications of the items to be procured are not prepared in a manner which is likely to benefit any particular company.
In this regard, it will be the responsibility of the concerned programme head to send the requisition as per the technical specifications of the items approved in the PIP and to procure the items included in the proposal.
(4) The prescribed procurement procedure should be carried out in accordance with the provisions of the revised rule book of procedures for office procurement to be carried out by government departments published under the Government Decision, Industry, Energy and Labor Department, No. 2014/ PR No. 82/ Part-III/ Industry-4, dated December 1, 2016.
(5) The rates of the proposed purchases are estimated at the time of granting administrative approval. Therefore, the price should be determined at the end of the purchase process. It should be ensured that the price is less than the market price and not more than the rate at which the supplier has supplied the item to other places.
(6) Pre/ post dispatch random sample inspection of the items to be purchased should be done to ensure that only the items with proper and correct specifications are purchased.
Page 4 of 6
# Page 5
Government Resolution No: PRASHAMA-1221/ PR No. 04/ HEALTH-7
(7) Storage and distribution of the items to be purchased after supply, supply chain management and inventory management should be done in a proper manner to ensure that these items do not remain unused and are used in a timely manner.
(8) The expenditure for the said procurement shall be met from the grants sanctioned under the head PIP FMR Code 6.2.23.2 and PIP FMR Code 6.2.23.1 for the year 2022-23 and 2023-24 of the Project Implementation Plan. Also, it should be ensured that the purchase is completed within the prescribed period of administrative approval.
(9) Also, it should be ensured that there is no duplication in the purchase of these items.
The Central Vigilance Commission (CVC) guidelines should be strictly followed while implementing the entire procurement process.
30/ Part- 2/2013/ Regulations, dated 17th April, 2015 in Annexure A to Rule No.4 of the Financial Powers Rules, 1978, Part-I Sub-Section-II. 7 in front of No. 6 conditions must be met.
(12) Supply orders shall be issued only after the approval of the Procurement Committee after the completion of the procurement process.
(13) After completion of the process, supply orders shall be issued only after approval of the Purchase Committee. Further, action should be taken in accordance with the provisions of the Government Resolution, Public Health Department, No: Purchase-2016/ PR No. 240/ Health-8, dated 26th July, 2017.
The Commissioner (Health Services) and Mission Director, National Health Mission, Mumbai, Director (Health Services), Directorate of Health Services, Mumbai and the Programme Head shall be solely responsible for ensuring that the conditions and conditions mentioned in the above Annexure (1) to (13) are fulfilled and the procurement is as per the norms and requirements.
Government Resolution, Department of Finance, vide No. 2013/ P.S. 30/13/ Regulations, Part-II, dated 17th April, 2015, in the Financial Powers Rules, 1978, Part I, Sub-Section-II, Section 4, Rule No. Under Section 7, the administrative department has been given full powers to approve the purchase of implements, spare parts and activity kits.
Page 6 of 5
# Page 6
Government Resolution No: PRASHAMA-1221/ PR No. 04/ HEALTH-7